Insmed reported $119.88M in Equity Capital and Reserves for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Equity Capital And Reserves Change
DBV Technologies DBVT:US 82.06M 17.21M
Acelrx Pharmaceuticals ACRX:US $ -38.27M 2.38M
Alimera Sciences ALIM:US $ -8.6M 6M
Biomarin Pharmaceutical BMRN:US $ 4391.31M 120.58M
Cytokinetics CYTK:US $ 116.26M 127.6M
Dynavax Technologies DVAX:US $ 287.48M 65.11M
Gilead Sciences GILD:US $ 19927M 1142M
Heron Therapeutics HRTX:US $ 23.96M 53.61M
Insmed INSM:US $ 119.88M 290.59M
Mirati Therapeutics MRTX:US $ 1249.28M 147.76M
Novartis NVS:US $ 61540M 6115M
Ophthotech OPHT:US $ 333.15M 27.37M
Regeneron Pharmaceuticals REGN:US $ 19914.7M 1145.9M
Sarepta Therapeutics SRPT:US $ 856.89M 71.12M
Seattle Genetics SGEN:US $ 2998.47M 66.67M
Ultragenyx Pharmaceutical RARE:US $ 796.42M 126.14M
Vertex Pharmaceuticals VRTX:US $ 10907M 807M